The ACC/ AHA in collaboration with 11 other societies have updated the recommendations for clinicians on the prevention, detection, evaluation & management of high blood pressure in adults.

GINA 2025 highlights personalized asthma care via the Assess–Adjust–Review cycle. Diagnosis is supported by clinical evaluation, spirometry/PEF, and biomarkers. ICS-formoterol is preferred for control and relief, with stepwise escalation.

Women treated with chemotherapy or chemoradiotherapy during childhood, adolescence, or young adulthood (CAYA) have an increased risk of preterm delivery, a meta-analysis found. Chemoradiotherapy raised preterm birth risk by 3.4-fold versus untreated controls and 1.93-fold versus chemotherapy alone. Even chemotherapy alone increased risk by 1.78-fold. Live-birth rates were unaffected.

Patients with ostomies face heightened risk of severe AKI (ostomy-AKI) soon after surgery, mainly from hypovolemia. Compared to general AKI, ostomy-AKI patients more often had stage 3 disease (82.9% vs 63.9%), experienced higher major adverse kidney events (MAKE) at 30-90 days (65.9 vs 49.3%; OR 2.4), and showed increased mortality (59.5% vs. 37%). Close post-op renal monitoring is crucial to reduce these risks.

Patients with bullous pemphigoid (BP) face a 66% higher risk of osteoporosis (aHR 66) and a 23% higher risk of femoral head fractures (FHF; aHR 1.23) compared to matched controls, a large study reports. Systemic corticosteroids were linked to a 59% higher osteoporosis risk than topical therapy (HR 1.59), with risk further amplified when combined with immunosuppressants. FHF carried a higher mortality (HR 1.42).

A new AI-enhanced ECG model, AIRE-CHB, accurately identified patients at risk of CHB. In over 1.1 million ECGs, it predicted CHB within a year with an AUROC of 0.889 (C index 0.836) vs 0.594 for bifascicular block assessment. Patients in the high-risk group had an 11.6-fold higher risk of incident CHB than the low-risk group, highlighting its potential as a valuable risk stratification tool.